Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Torcetrapib Stories

2013-10-14 23:20:48

Reportbuyer.com just published a new market research report: Cardiovascular Disease: Recent Drug Advances and Impending Risks. London (PRWEB) October 14, 2013 There are nearly 300 medicines in clinical development to treat cardiovascular disease. This new research report examines in detail the key areas of the cardiovascular (CV) market, gathering inside opinion of cardiologists, to highlight the dynamic changes that are underway in this multibillion dollar marketplace. Successful...

2013-08-20 12:23:36

Despite Strong Genericization of the Dyslipidemia Market, Statins Will Remain the Sales-Leading Drug Class Through 2022, According to a New Report from Decision Resources BURLINGTON, Mass., Aug. 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the dyslipidemia market will grow to just over $31 billion in 2022, at an annual rate of 2 percent from 2012. The launch of antidyslipidemic...

Conflicting Opinions On HDL As 'Good' Cholesterol
2012-05-18 09:28:44

Connie K. Ho for RedOrbit.com High-density lipoprotein, otherwise known as HDL, was thought to be “good” cholesterol. However, a new study, based on databases of genetic information, disproves the HDL theory and states that rising HDL may not have any change to heart disease risk. As such, people who have inherited genes that have a high amount of HDL do not have any less of a chance of having heart disease than those who have inherited genes that have lower levels of HDL....

2011-11-15 19:31:45

Researchers at Cleveland Clinic reported today that administration of a new drug— evacetrapib — can dramatically increase HDL (good) cholesterol, while significantly lowering LDL (bad) cholesterol). At the highest tested dosage, the levels of HDL more than doubled. The study was presented today by lead investigator Stephen Nicholls MD PhD, Cardiovascular Director of the Cleveland Clinic Coordinating Center for Clinical Research (C5), at the American Heart Association's...

2011-11-15 09:53:01

Among patients with sub-optimal low-density lipoprotein cholesterol (LDL-C) or high-density lipoprotein cholesterol (HDL-C) levels, use of the drug evacetrapib alone or in combination with statin medications was associated with significant increases in HDL-C levels and decreases in LDL-C levels, according to a study appearing in the November 16 issue of JAMA, a theme issue on cardiovascular disease. The study is being released early online to coincide with its presentation at the American...

6fc0a6e0493b5d09890cfcaf2104d165
2011-08-04 10:34:48

US regulators will be considering a plan from pharmaceutical giant Pfizer to introduce an over-the-counter version of its top-selling heart drug Lipitor. Selling the popular anti-cholesterol drug without a prescription could help Pfizer's bottom line as the company faces a "patent cliff" that threatens to erode profits during the next few years, according to the Wall Street Journal. Lipitor will soon lose patent protection and face competition from cheaper generic versions of its popular...

2011-07-19 07:40:34

(Ivanhoe Newswire) -- A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to this study. The drug, Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor, a type of drug that increases levels of high-density lipoproteins (HDLs, or "good" cholesterol). The study found that 6,661 people with type 2 diabetes "“ also known as "adult-onset" diabetes "“...

2011-07-18 16:15:32

A medicine designed to improve levels of "good" cholesterol may also help control blood sugar in people with diabetes who are taking cholesterol-lowering drugs, according to a new analysis in Circulation: Journal of the American Heart Association. Researchers made the finding while analyzing data from a clinical trial on the drug torcetrapib that was halted five years ago. Torcetrapib is a cholesterol ester transfer protein (CETP) inhibitor, a type of drug that increases levels of...

2011-05-04 06:15:00

HOERSHOLM, Denmark and SAN DIEGO, May 4, 2011 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the research and development of mRNA and microRNA targeted therapies, today announced that it has advanced SPC5001 into Phase 1 clinical trials for the treatment of high cholesterol. SPC5001 is a mRNA-targeted drug that inhibits the exciting new target, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), a protein involved in removing low density...

2010-05-26 09:58:35

HDL cholesterol can transform from good to bad actor in heart disease process We've all heard about the importance of raising HDL, or the so-called "good" cholesterol, and lowering LDL, or "bad" cholesterol, to improve heart health. While we've come to assume HDL cholesterol is an inherently good thing, a new study shows that for a certain group of patients, this is not always the case. The study is the first to find that a high level of the supposedly good cholesterol places a subgroup of...